Windlas Biotech Limited has informed the Exchange regarding Closure of Buy Back with effect from May 16, 2026
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Windlas Biotech Limited has completed its share buyback program, extinguishing 4,70,000 equity shares (2.2% of outstanding shares) at INR 1,000 per share, totaling approximately INR 47 crore. The buyback was conducted via tender offer route with the tendering period from April 30, 2026 to May 7, 2026, and shares were extinguished on May 16, 2026. Post-buyback, the paid-up equity share capital reduced from INR 10.55 crore to INR 10.32 crore. The buyback price of INR 1,000 represents a massive premium over the face value of INR 5 per share (19,900% premium). Promoter holding effectively increased from 61.90% to 63.31% as their share count remained unchanged while total shares reduced.
Minor positive impact expected as remaining shareholders benefit from a 20% premium exit opportunity (assuming market price around INR 833). The small 2.2% reduction limits EPS impact. The buyback signals management confidence but at a modest scale.